TLDR:
- GlaxoSmithKline (GSK) and Flagship Pioneering launch a partnership to develop up to 10 new drugs and vaccines, starting with respiratory and immunology indications.
- The collaboration could generate over $7 billion for Flagship Pioneering and its portfolio companies.
GlaxoSmithKline (GSK) has announced a partnership with Flagship Pioneering to develop up to 10 new drugs and vaccines, focusing initially on respiratory and immunology indications. The collaboration aims to combine GSK’s therapeutic area expertise with Flagship’s ecosystem of companies to accelerate the development of transformational treatments and vaccines. This partnership will see the identification and acceleration of promising scientific concepts for further research, with an initial focus on respiratory and immunology areas.
Flagship and its bioplatform companies will receive up to $720 million from GSK based on achieving various milestones and royalties for each program acquired. GSK’s recent acquisition of Aiolos Bio, a company specializing in asthma treatments, is part of its efforts to expand its respiratory portfolio. The collaboration is the latest in a series of partnerships between biopharma giants and Flagship Pioneering to develop new therapies and vaccines.
Flagship’s primary portfolio includes companies focused on life sciences, human health, and AI, such as Moderna and Generate:Biomedicines. The partnership with GSK will enable Flagship to tap into its drug development unit, Pioneering Medicines, to deliver breakthrough medicines for patients with unmet needs in respiratory and immunology treatments.
